OfferingRegistry
Offerings / Regulation CF / Safa Body LLC

Safa Body LLC

Regulation Crowdfunding offering on Honeycomb Credit · Form C filed February 27, 2026 · New York, New York

DebtEarly revenueLimited Liability Company, New YorkConsumer productsPremium body care and fragrance products

Safa Body LLC, doing business as Safa Body, sells fragrance-forward body oils and related body care products, having launched in 2022 and reporting revenue of $435,929 in 2024 and $321,140 in 2025. The company is operating (early revenue stage) and is offering subordinated secured promissory notes with a target of $25,000 and a maximum of $124,000.

Registry notesThe filing states that the Company does not need offering funds to remain in business, and it reports a 2025 net income of $210,274 while operating cash flow was negative and cash declined. Notes are personally guaranteed by Sarah Uddin, are secured by a second-priority lien (the Security Agreement describes a blanket lien in the Company's assets, while the NPA draft also contains a purchase money lien reference), and the Form C's Schedule of Interest and Maturity is inconsistent with the 60-month maturity described in the Details section.

Profile details below were extracted automatically from the issuer's filing documents. Figures in the financial table come directly from the SEC's structured Form C data.

Offering terms

Security
Debt
Maximum
$124,000.00
Price
$1.00 per unit
Pricing method
Pro-rated portion of the total principal
Deadline
April 2, 2026
Oversubscriptions
Accepted, first-come, first-served basis
Intermediary
Honeycomb Portal LLC
Funding portal, SEC file 007-00119
Intermediary fee
8.5% of the total offering amount upon a successful raise. Platform Fee corresponding to selected level of service. 3% investment fee capped at $50. Credit Card: 4.5%, capped at $1,000. Honeycomb Wallet: 0%; Hybrid (HW + ACH): 2%, capped at $30
Intermediary equity
None

Financials as filed

ItemMost recent FYPrior FY
Revenue$321,140$435,929
Cost of goods sold$69,502$170,097
Net income (loss)$210,274$218,966
Total assets$70,493$62,751
Cash and equivalents$15,223$20,751
Accounts receivable$35,270$30,000
Short-term debt$10,233$45,507
Long-term debt$0$0
Taxes paid$0$0

Two fiscal years as reported on the Form C cover sheet. 8 employees. Offered in 64 states.

Use of proceeds

At the $25,000 minimum: $22,830 net after intermediary fee of $2,125 and admin fee of $45. At the $124,000 maximum: inventory $60,000, marketing and advertising $50,000, and product development and clinical research $14,000 (total $124,000), with net proceeds of $113,415 after intermediary fee of $10,540 and admin fee of $45. The filing states funds will be used in descending priority order and management may use funds differently than stated.

Valuation

Not stated. The notes are valued at their face amount; the terms were determined by the owner based on the owner's opinion about the value of the project.

Prior raises

Not stated

Financial statements

Not audited or reviewed by an independent accountant. Financial information is certified by the principal executive officer, Sarah Uddin (Exhibit C officer certificate).